Penn, Novartis end 7-year R&D alliance, will narrow scope of collaboration - (Philadelphia Business Journal via NewsPoints Desk)

  • Novartis and the University of Pennsylvania have concluded a seven-year R&D alliance that produced the first CAR T-cell therapy approved by the FDA, reported Philadelphia Business Journal.

  • The partnership will continue under a more narrow portfolio of cell therapy clinical trials, the news source said. 

  • In 2017, the FDA approved Novartis' CAR T-cell therapy Kymriah for pediatric and young adult patients with acute lymphoblastic leukemia and non-Hodgkin lymphoma.

  • Robert Vonderheide, director of the university's Abramson Cancer Center, noted that the region's efforts to advance cell and gene therapy have spawned 30 companies that have created 3000 jobs and attracted more than $1 billion in investments.

To read more NewsPoints articles, click here.

Reference Articles